In early August, Cuba received the first batch of a Russian-made diagnostic product to detect tuberculosis in the early stages. The first delivery of “Tuberculin” manufactured by FSUE SPbSRIVS FMBA was successfully shipped as part of cooperation between the Russian company and the Cuban Ministry of Health. “Undoubtedly, this is a milestone both for us and for the whole of Latin America. Every day, tuberculosis kills 4400 people worldwide and early diagnosis is recognized as an effective way to combat this disease.
Last weekend, Cuba received the first batch of 54 thousand doses of a diagnostic product for detecting tuberculosis produced by SPbSRIVS. We expect to broaden the geography of supplies over to other Latin American countries in the future,” said Director of SPbSRIVS Viktor Trukhin. The Instituto Latinoamericano de Biotecnología MECHNIKOV, a joint Russian-Nicaraguan enterprise for immunobiological production, acted as a partner in the Tuberculin delivery. The logistics and supply chain management, with respect to the “cold” chain requirements, was provided by the DHL Global Forwarding experts. “The countries of the region, as well as the Pan American Health Organization (PAHO), are showing increasing interest in the Russian-made pharmaceutical product “Tuberculin”, especially because of its long-standing use, proven efficacy, and good value for money as compared to foreign equivalents," said Stanislav Uiba, General Director of the Instituto MECHNIKOV. Earlier in 2017, SPbSRIVS routinely delivered 967 thousand doses of influenza vaccine to Latin American countries. The Russian vaccine will be used to prevent influenza in Cuba and Nicaragua.
